CELLINK, the leading bioconvergence company in the world, announced the launch of the BIO MDX™ Series, the next generation of bioprinters designed for high-throughput biofabrication and precision 3D bioprinting for biomedical manufacturing, including biocompatible medical devices.
Over the past 5 years, as 3D bioprinting has increasingly become the method of choice for researchers in tissue engineering, cell culturing and regenerative medicine, there has been a greater need for improved automation, precision, and reproducibility across biofabrication methods. With up to six printheads, nanoliter and picoliter dispensing channels and easy robotic integration, the BIO MDX series bioprinters have been specifically designed for high-throughput biofabrication to meet the demands of the ever-advancing cell-based technologies.
The BIO MDX series is backed by more than 25 years of research and development. Equipped with technology found on SCIENION arrayers, these bioprinters represents the first cross business systems for the CELLINK Group. Demonstrating a successful integration of SCIENION’s intellectual property with CELLLINK’s 3D bioprinting expertise. This launch further illustrates our commitment to the bioconvergence revolution by bringing forward new technologies to solve the most pressing challenges in the life sciences.
[penci_related_posts taxonomies=”undefined” title=”Related Posts” background=”” border=”Blue” thumbright=”no” number=”4″ style=”grid” align=”none” displayby=”tag” orderby=”random”]
According to Héctor Martínez, CELLINK CTO, “Leveraging synergies across the group, this launch represents an important step toward developing systems and solutions that bring CELLINK closer to patient care and creating the future of medicine. Biomedical manufacturing has desperately needed improved technologies, and the BIO MDX Series provides just that.”
Artur Aira, CELLINK 3D bioprinting Business Area Manager expressed, “3D bioprinting is increasing in stature within the life sciences. In order to grow with our customers, it is essential that we continue to push the industry forward and develop the latest and greatest technologies. The BIO MDX series represents exactly this and goes a long way in strengthening what is already a robust 3D bioprinting product portfolio.”
BIO MDX™ is the registered trademark of Cellink AB
About CELLINK: Founded in 2016, CELLINK is the leading bioconvergence company in the world that provides technologies, products and services to create, understand and master biology.
About Manufactur3D Magazine: Manufactur3D is an online magazine on 3D Printing. Visit our Tech News page for more updates on 3D Printing Technology News. To stay up-to-date about the latest happenings in the 3D printing world, like us on Facebook, follow us on LinkedIn and Twitter.